Chapter 7 210 METHODS Study design and participant enrolment RECoVERED is a prospective cohort study of adults aged 16-85 with SARS-CoV-2 infection between May 2020 and June 2021 in Amsterdam, the Netherlands. Full details of study procedures have been published elsewhere[1]. Briefly, participants were enrolled within 7 days of diagnosis (at the Public Health Service of Amsterdam) or hospital admission (at the Amsterdam University Medical Centres [UMC]). All participants had laboratoryconfirmed SARS-CoV-2 infection. RECoVERED was approved by the medical ethical review board of the Amsterdam University Medical Centres (METC NL73759.018.20). All participants provided written informed consent. For the current analysis, we included participants with samples from at least two different time-points and with follow-up of at least 3 months following SARS-CoV-2 infection. We additionally included reference u samples from SARS-CoV-2-uninfected, healthy individuals (i.e., no comorbidities) collected between March 2020 and November 2021. These samples were randomly selected from a prospective serologic surveillance cohort study among hospital healthcare workers in the Amsterdam UMC (S3 study; METC NL73478.029.20)[16]. Surveys on socio-demographic, clinical and symptom-related data During the first month of follow-up, trained study staff interviewed participants on the presence of 20 different COVID-19 symptoms, took physical measurements, and recorded participants’ past medical and socio-demographic characteristics. Recorded symptoms included: fatigue, cough, fever, rhinorrhoea, sore throat, dyspnoea, loss of smell and/or taste, chest pain, headache, abdominal pain, confusion, arthralgia, myalgia, loss of appetite, wheeze, skin rash, nausea and/or vomiting, diarrhoea, earache, and spontaneous bleeding. Between months 3 to 12 of follow-up, monthly online questionnaires on the presence of the same 20 COVID-19 symptoms were completed by participants. Lung function tests including diffusion capacity (DLCO) were performed at 1, 6 and 12 months after illness onset (detailed methods described elsewhere[17]). Biological sampling Serum samples were collected at day 0 and 7 and subsequently at months 1, 3, 6, 9, 12, 18 and 24 of follow-up. Additional serum samples were collected per protocol within 24 hours of receiving a COVID-19 vaccination and 7 and 28 days following each COVID-19
RkJQdWJsaXNoZXIy MTk4NDMw